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Abstract
Central core disease is a myopathy often arising from mutations in the type 1 ryanodine receptor (RYR1) gene,
encoding the sarcoplasmic reticulum calcium release channel RyR1. No treatment is currently available for this
disease. We studied the pathological situation of a severely affected child with two recessive mutations, which
resulted in a massive reduction in the amount of RyR1. The paternal mutation induced the inclusion of a new in-
frame pseudo-exon in RyR1 mRNA that resulted in the insertion of additional amino acids leading to the
instability of the protein. We hypothesized that skipping this additional exon would be sufficient to restore RyR1
expression and to normalize calcium releases. We therefore developed U7-AON lentiviral vectors to force exon
skipping on affected primary muscle cells. The efficiency of the exon skipping was evaluated at the mRNA level,
at the protein level, and at the functional level using calcium imaging. In these affected cells, we observed a
decreased inclusion of the pseudo-exon, an increased RyR1 protein expression, and a restoration of calcium
releases of normal amplitude either upon direct RyR1 stimulation or in response to membrane depolarization.
This study is the first demonstration of the potential of exon-skipping strategy for the therapy of central core
disease, from the molecular to the functional level.
Introduction
T
ype 1 ryanodine receptor (RyR1), encoded by theRYR1
gene (MIM#180901), is the main sarcoplasmic reticulum
calcium channel in skeletal muscles. RyR1 and its major
partner in the calcium release complex, the voltage gated
calcium channel—dihydropyridine receptor (DHPR)—are
responsible for the excitation–contraction coupling process
(Lanner et al., 2010).
Mutations in the RYR1 gene have been associated with con-
genital myopathies: central core disease (CCD; MIM#117000)
(Lynch et al., 1999; Monnier et al., 2001; Davis et al., 2003) and
multiminicore disease (MIM#602771) (Feirrero et al., 2002;
Jungbluth et al., 2002; Monnier et al., 2003). CCD is characterized
by the presence of cores in type 1 muscle fibers. Those are large
areas of abnormal myofibrillar architecture characterized by
sarcomeric disorganization and absence of mitochondria
(Monnier et al., 2001; De Cauwer et al., 2002). CCD presents
either an autosomal dominant or a recessive transmission pat-
tern and is clinically heterogeneous. Clinical presentation ranges
from mild phenotype, with moderate hypotonia during early
childhood, delayed motor abilities, and slowly progressive
proximal muscle weakness, to severe phenotype, including fetal
akinesia, respiratory insufficiency at birth, and generalized
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muscle weakness (Romero et al., 2003; Jungbluth, 2007). No
treatment is currently available for this disease.
We have previously described a patient affected by a
recessive form of the disease with a very severe phenotype
(Monnier et al., 2008). He presented at birth with a major
respiratory insufficiency associated with hypotonia. At six,
he showed a generalized muscle weakness and significant
scoliosis. He was unable to walk and was under respiratory
assistance. A muscle biopsy, performed when he was 1 year
old, showed the presence of well-delimited large cores in
type 1 fibers. He was diagnosed as being affected with
CCD. Genetic analysis showed that he was compound
heterozygous for the RYR1 gene, with one mutation on the
maternal allele of incomplete penetrance leading to a STOP
codon, and a deep intronic mutation on the paternal allele
leading to the introduction of an additional exon, called
pseudo-exon 101bis. The consequence of both mutations
was a massive loss in the amount of the RyR1 protein, al-
though RyR1 transcript levels were unaffected (Monnier
et al., 2008).
The exon-skipping therapeutic strategy has been success-
fully applied to different genetic diseases (Wein et al., 2010;
Hammond and Wood, 2011; Taniguchi-Ikeda et al., 2011;
Spitali and Aartsma-Rus, 2012). The principle of exon skip-
ping is to block some specific splice sites during mRNA
maturation with antisense oligonucleotides (AONs) in order
to restore the reading frame at the transcript level. This ap-
proach has been used in mouse and dog animal models of
Duchenne muscular dystrophy (Goyenvalle et al., 2004; Vulin
et al., 2012), demonstrating its ability to restore an internally
truncated but functional protein, and is now used in clinical
trials (Cirak et al., 2011). Initially focused on Duchenne
muscular dystrophy, exon skipping has been further applied
to other muscle diseases, for example, the Fukuyama mus-
cular dystrophy and dysferlinopathy (Wein et al., 2010;
Taniguchi-Ikeda et al., 2011). In the present study, we have
developed an exon-skipping strategy to force the skipping of
the additional 101bis pseudo-exon in RyR1 pre-mRNA and
thus restore the expression of a normal protein. This strategy,
applied to human primary muscle cultures having the mu-
tation, led to an increase in the amount of the RyR1 protein.
In addition, the restored protein was functional, as observed
by normalization of the amplitude of calcium releases in
treated cells. This study is the first demonstration of a pos-
sible treatment for an RyR1-related myopathy.
Materials and Methods
Ethics statement
Investigations on patient material were performed after
signature of an informed consent by the patients according to
French regulation and have received approval from the local
ethics committee (Comite´ de Protection des Personnes Sud-Est).
RYR1 reference sequence
The RYR1 sequence used in this work is accessible as NCI
RefSeq NM_000540.2.
Quantitative Western blot analysis
The amount of RyR1 present in the muscle sample was
determined by quantitative Western blot analysis using
antibodies directed against RyR1 (Marty et al., 1994) and
normalized to the amount of c-sarcoglycan (antibody from
Novo Castra) as described previously (Monnier et al., 2008).
Signals were detected using a chemiluminescent HRP sub-
strate and quantified using a ChemiDoc XRS apparatus
(Biorad) and the Quantity One software (Biorad).
Cell culture, cell sorting, and differentiation
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (Invitrogen).
Fetal muscle biopsies were obtained from 14-week-old
fetuses after medical abortion in the case of the mutant fetal
(MF) cells and legal in-request abortion in the case of the
control fetal (CF) cells. Primary cultures obtained from these
biopsies were further enriched in myoblasts using a MACS
sorting kit (CD56 microbeads; Miltenyi Biotec SAS), accord-
ing to manufacturer’s protocol. The amount of myoblasts in
each culture was evaluated by desmin immunolabeling and
was estimated to 83% for MF cells and 46% for CF cells.
MF and CF myoblasts were grown in proliferation me-
dium (HamF10 supplemented with 20% fetal bovine serum,
2% Ultroser [Pall Biosepra], and 1% penicillin/streptomycin).
Differentiation was induced by shifting cells to differenti-
ation medium (DMEM 1% glucose supplemented with
2% horse serum), during 4 days for reverse transcriptase–
polymerase chain reaction (RT-PCR) experiments, or 8–10
days for RyR1 protein detection and calcium imaging
experiments.
Reverse transcriptase–polymerase chain reaction
Cells were lyzed in TRIzol reagent (Invitrogen, Life
Technologies SAS) and total RNA was extracted with the
Ambion PureLink kit (Life Technologies SAS) according to
the manufacturer’s instructions. Complementary DNA was
synthesized from 500 to 750 ng of total RNA using 0.5 ll of
Transcriptor (Roche) and 0.3 lg of oligo-dT as described
(Monnier et al., 2001). PCR with 25 amplification cycles were
then performed with the following primers: pCIneoF and
T3R for the minigene splicing assay; CCL28/2F and CCL28/
2R for amplification of the fragment of RYR1 comprising
exons 101 and 102. Primers (see sequences in Table 1) were
produced and purified by Eurogentec. After PCR, the am-
plified products were separated by electrophoresis on aga-
rose gels and quantified with a Chemidoc XRS apparatus
and Quantity One software (Bio-Rad).
Minigene splicing assay
A PCR was performed on the genomic DNA of individual
III.1 with MluI-101bis-F and SalI-101bis-R primers (Table 1)
to amplify a region of 496 bp encompassing the c.14646+
2563C>T mutation, and the amplified fragments from both
alleles were inserted in a pCIneo plasmid modified as de-
scribed previously (Roux-Buisson et al., 2011). Two minigene
plasmids were cloned and sequenced, one with the wild-type
sequence, called C construct, and one with the c.14646+
2563C>T mutation, called M construct. Transfections were
performed on 3.105 HEK293 cells using ExGen500 (Euro-
medex) with a DNA:ExGen ratio of 3:10, according to man-
ufacturer’s instructions. Forty hours after transfection, cells
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were collected by trypsination and processed for RT-PCR,
using primers pCIneoF and T3R.
AON design and transfection
AONs were chosen according to several criteria: type and
accessibility of the target and stability of the AON-pre
mRNA binding energy (Aartsma-Rus et al., 2009). The 101bis
pseudo-exon and its intronic junctions in the RYR1 sequence
were analyzed by the Human splicing Finder software
(Desmet et al., 2009), in order to identify the splice sites and
to find potential exonic splicing enhancers (ESE). The ac-
cessibility was determined by analysis of the pre-mRNA
with Mfold software (Zuker, 2003): open structures in the
pre-mRNA strand were considered to have a better accessi-
bility than apparied ones. Within these regions defined as
interesting targets (splice sites or ESE in the pseudo-exon),
seven AONs were designed according to their binding en-
ergy using the ‘‘Oligowalk’’ option in the RNA structure 4.5
software (Reuter and Mathews, 2010). The sequences of the
AONs are indicated in Table 1. The seven 2¢O-methyl AONs
with a phosphorothioate backbone were produced and pu-
rified by Alpha DNA.
MF or CF myoblasts (105 cells) were seeded in 35mm
dishes and were transfected with 8.5 ll of Exgen500 and
500 nM AONs (Aartsma-Rus et al., 2003). After 2 days in the
proliferation medium, the cells were switched to a differen-
tiation medium. After 24 hr of differentiation, cells under-
went a second transfection following the same protocol and
were collected 3 days after for RT-PCR analyses (4 days post-
differentiation).
U7 small nuclear RNA lentiviral vectors
and transduction
The U7 DNA fragments were engineered from the previ-
ously described U7SmOPT (Gorman et al., 1998; Wein et al.,
2010), with antisense sequence targeting the histone pre-
mRNA replaced by the specific antisense sequences (Table 1)
targeting the human pre-mRNA of RYR1. The U7-Ctrl and
U7-D +E fragments were subcloned into a plasmid pRRL–
cPPT–mcs–WPRE, derived from the pRRL–cPPT–hPGK–
eGFP–WPRE construct (Naldini, 1998), and sequences of
constructs were checked by sequencing. Lentiviral vectors
were produced at Genethon as previously described by
transient quadri-transfection into HEK293T cells. Viral titers
(infectious particles) were determined by transduction of
HCT116 cells and assayed by quantitative real-time PCR on
genomic DNA (Charrier et al., 2005). For myoblast trans-
duction, 3· 105 MF or CF cells were seeded in a 500 ll drop
of a proliferating medium in 60mm culture dishes. Lentiviral
particles (MOI 300) were added in the drop, and after 8 hr of
incubation at 37C, 2ml of proliferating medium was added
and cells were allowed to grow for 48 hr. After amplification
to 107 cells, cells were trypsinized and split into several
dishes to perform RT-PCR, immunofluorescence and calcium
imaging assays in parallel.
Immunofluorescence microscopy
Myotubes (8–10 days of differentiation) grown on plastic
Ibidi dishes (Biovalley) coated with laminin were washed
with PBS and fixed 6min in methanol at - 20C. Myotubes
were then processed for immunolabeling with a monoclonal
antibody against myosin heavy chain (MyHC), as a marker
of differentiation (MF20; Developmental Studies Hybridoma
Bank, NICHD, University of Iowa) and a polyclonal anti-
body against RyR1 (Marty et al., 1994). After a 15min per-
meabilization with PBS-0.1% Tween 20 (PBS-T), cells were
incubated for 1 hr 30min with primary antibodies in PBS-T at
room temperature. After three washes with PBS-T, cells were
incubated for 30min at room temperature with fluorescent
secondary antibodies, and washed again before mounting in
Fluorsave (Merck Chemicals). The secondary antibodies
were either coupled to Alexa-488 (Molecular Probes, Life
Technologies SAS) or Cy3 ( Jackson ImmunoResearch Eur-
ope). The samples were analyzed using a Leica SPE confocal
laser scanning microscope (Leica Microsystemes SAS).
RyR1 quantification and myotubes width
measurements by image analysis
For RyR1 quantification in myotubes, images of five focal
planes separated by 1.5 lm were acquired with identical
confocal settings between the different images and the dif-
ferent experimental conditions (transduced and non-
transduced myotubes). Settings were adjusted in order to
avoid any pixel saturation, both for RyR1 and for MyHC
staining. Z-projections of the five planes were performed and
the Sum images were used for quantification, as described
below. Relative expression levels of the RyR1 protein in
myotubes were quantified using ImageJ software (version
1.44i, NIH) and a home-made macro. The macro performed
different operations: myotubes were first delineated in re-
gions of interest (ROIs) using the MyHC image; the mean
pixel intensities of the MyHC staining were measured inside
ROIs and MyHC background was measured outside the
ROIs; the same ROIs were reported on the RyR1 staining
image, and the RyR1 signal mean intensity and the RyR1
background were measured. The ratio of RyR1 to MyHC
intensities was calculated as follows: (RyR1 mean pixel
Table 1. Sequences of Primers and Antisense
Oligonucleotides Used in This Study
Primer Sequence Use
pCIneoF 5¢ gttcaattacagctcttaag 3¢ RT-PCR
T3R 5¢ aattaaccctcactaaaggg 3¢ RT-PCR
CCL28/2F 5¢ tctggaagttcggggtcatctt 3¢ RT-PCR
CCL28/2R 5¢ gccatgcggtgtcgtatcaa 3¢ RT-PCR
MluI-101bis-F 5¢ gggacgcgtagagacacagg
ccacaatcc 3¢
Minigene
SalI-101bis-R 5¢ ggggtcgacgagtgcaatggcg
tgatct 3¢
Minigene
U7-D +E
antisense
5¢ ccacagcgcccggcauacacuu
guucuuc 3¢
Lentivirus
U7-CTRL
antisense
5¢ gguguauugcaugauaugu 3¢ Lentivirus
AON-A 5¢ ucauccuagaguaaaaacua 3¢ Exon skipping
AON-B 5¢ gaacacagucauccaagagu 3¢ Exon skipping
AON-C 5¢ augugagagaacacagucau 3¢ Exon skipping
AON-D 5¢ guucuuuccguguccccagg 3¢ Exon skipping
AON-E 5¢ ccacagcgcccggcauacac 3¢ Exon skipping
AON-F 5¢ ggauuaaaagcgugagccac 3¢ Exon skipping
AON-G 5¢ augauccaccuaccuuggcc 3¢ Exon skipping
RT-PCR, reverse transcriptase–polymerase chain reaction.
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intensity -RyR1 global background)/(MyHC mean pixel
intensity -MyHC global background). For myotube width
measurements, the maximal width per myotube was mea-
sured on MyHC z-projections images, using ImageJ soft-
ware.
Calcium imaging assays
Changes in intracellular calcium were measured using the
calcium-dependent fluorescent dye Fluo4-AM (Molecular
Probes, Life Technologies SAS), as described before (Rezgui
et al., 2005). Myotubes were incubated for 1 hr at room
temperature with Fluo-4-AM 10lM, in Krebs buffer (136mM
NaCl, 5mM KCl, 2mM CaCl2, 1mM MgCl2, 10mM HEPES
pH 7.4). Uptake of the dye was facilitated by the addition of
0.02% pluronic F-127 acid (Sigma). After loading, myotubes
were washed for 1 hr at 37C to allow de-esterification of the
dye. Calcium imaging was performed in Krebs buffer.
4-Chloro-m-Cresol (CmC) was prepared as stock solution in
Krebs buffer and used at final concentrations of 500 lM. In
the depolarization solution, NaCl was replaced by KCl
(140mM final concentration). Fluorescence was measured by
confocal laser scanning microscopy, using a Leica TCS-SPE
operating system, in the xyt mode. The fluorescence images
were collected every 0.9 sec, during 2–4min, and then ana-
lyzed frame by frame. Fluorescence curves are expressed as a
function of time, as DF/F0, where F0 represents the baseline
fluorescence immediately before depolarization and DF
represents the fluorescence changes from baseline. Data are
given as mean – SEM, and n represents the number of myo-
tubes in each condition.
Statistics
Statistics were performed using Student’s t-test or analysis
of variance followed by Bonferroni t-test for multiple com-
parisons, on Prism 6.0 software (GraphPad), with n =number
of myotubes in at least three different experiments, and after
checking the normal distribution of the samples.
Results
Case description
The proband (individual III:1; Fig. 1a), first described in
Monnier et al. (2008), harbored two RYR1 mutations, one
inherited from his father (c.14646 + 2563C >T), and one from
his mother (c.11778G >A). The c.1464+ 2563C>T change in
intron 101 of the paternal allele created a donor splice site
and activated an upstream acceptor site responsible for the
insertion of a 99 bp pseudo-exon, called 101bis, at the junc-
tion of exons 101 and 102 (Fig. 1c). Because the 101bis
pseudo-exon was in frame, this led to the insertion of 33
amino acids within the last luminal loop of RyR1 (Fig. 1d)
that is involved in the interaction between RyR1 and its
protein partner triadin (Lee et al., 2004). The mutation was
found in the proband’s father (individual II:2) and paternal
uncle (individual II:3), both mildly affected. On the maternal
allele, a silent c.11778G>A change of the last nucleotide of
exon 85 (p.Gln3926Gln) unveiled a cryptic donor site
downstream from the regular donor site. As a consequence
of an incomplete penetrance, the maternal mutation gener-
ated two transcripts. In the first transcript, the splicing was
unaffected and the presence of a CAA instead of a CAG
FIG. 1. Case description. (a) Pedigree of the family. Black
symbols denote the symptomatic individuals, gray symbols
correspond to pauci-symptomatic individuals, open symbols
indicate asymptomatic individuals, and question marks refer
to individuals with an unknown clinical status. The arrow
indicates the proband. Diamond symbol represents the fetus.
Signs + and - refer to the presence and absence of a mutation
in the RYR1 gene, respectively. (b) Western blot analysis of
the amount of RyR1 in a muscle biopsy from the patient (P,
ind III.1) compared with an age-matched control (C).
Amount of RyR1 was normalized to the amount of c-sarcoglycan.
(c) Representation of the consequences of the c.14646+
2563C>T paternal intronic mutation on the splicing of the
RYR1 pre-mRNA. The additional pseudo-exon inserted in
the mRNA after aberrant splicing is in gray. (d) Schematic
representation of the RyR1 protein with the approximate
localizations of the maternal c.11778G>A and paternal
c.14646+ 2563C>T mutations. The six transmembrane do-
mains of RyR1 are represented in gray, in the sarcoplasmic
reticulum membrane. RyR1, type 1 ryanodine receptor.
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codon did not modify the glutamine at position 3926. In the
second transcript, the use of the cryptic donor site resulted in
a premature STOP codon at position p.3926 + 4 (Monnier
et al., 2008). The mother (individual II:1) was considered
healthy.
A protein analysis performed on a muscle biopsy from the
proband’s uncle (individual II:3, who had only the c.14646+
2563C >T paternal mutation at heterozygous state) showed a
residual amount of RyR1 of 57% – 3% of a control, without
alteration of the amount of the RyR1 transcript (Monnier
et al., 2008). As this mutation induced the addition of 33
amino acids in the channel part of RyR1, it can be assumed
that this most probably led to an abnormal folding of the
protein and to its degradation. Because the maternal muta-
tion induced the presence of a premature STOP codon, the
amount of the RyR1 protein in muscles of the proband (III:1)
with the two mutations was expected be much lower than
that of his uncle (II:3). This very low amount of protein could
explain the severe phenotype of the proband (Monnier et al.,
2008). The amount of the RyR1 protein in a biopsy of the
proband III:1 was analyzed in the present study (Fig 1b).
Although evaluation of the RyR1 amount by Western blot
analysis could be performed only twice because of the lim-
ited biopsy available, it confirmed a major reduction in the
amount of RyR1 for the proband (35% of protein remaining
compared with an age-matched control biopsy) (Fig. 1b).
Mutation analysis
A prenatal diagnosis was subsequently performed in this
family and led to a medical abortion because the fetus (ind.
III:2; Fig. 1a) was bearing the two very same mutations
identified in the proband. Affected fetal primary muscle
cells, called MF cells, were produced from a muscle biopsy of
the fetus. CF primary muscle cells were produced from an
age-matched normal fetus. The effect of the c.14646+
2563C >T intronic mutation on RYR1 expression was studied
by RT-PCR using MF and CF cell cultures. An amplification
of RyR1 mRNA was performed on the region spanning nu-
cleotides 14438–15030 that contained exons 101 and 102. Two
amplicons were obtained in MF cells (Fig. 2a, lane 2): one of
normal 593 bp size, as in control CF cells (lane 1), and one of
692 bp size, which corresponded to the insertion of the 99 bp
of exon 101bis. This result on MF cells confirmed the inser-
tion of the pseudo-exon that was described for patient III:1
(Monnier et al., 2008). However, it was not possible to know
if the residual normal-sized 593 bp fragment was because of
incomplete penetrance of maternal or paternal mutation. The
penetrance of the paternal mutation was analyzed using a
minigene assay. The DNA sequence encoding the pseudo-
exon and its flanking 5¢ and 3¢ regions was inserted into a
pCIneo plasmid (Fig. 2b). Two constructs were developed,
one with the normal sequence as a control (C construct) and
one with the c.14646+ 2563C >T mutation (M construct).
Each minigene was transfected in HEK293 cells, which do
not express any endogenous RyR1. Two days after trans-
fection, an RT-PCR analysis of minigene splicing was per-
formed (Fig. 2b). Only one fragment was amplified from cells
transfected with the control C construct (Fig.2b, lane 1),
while two fragments were amplified from cells transfected
with the mutant M construct (Fig. 2b, lane 2). This confirmed
that the paternal intronic c.14646+ 2563C>T mutation by
FIG. 2. Characterization of the paternal c.14646 + 2563C >T mutation. (a) RT-PCR performed on CF and MF cells differ-
entiated during 4 days. RT-PCR amplification was performed on the region c.14438–15030 of RYR1 including exons 101 and
102. Size analysis of the amplified fragments showed the presence of a normal-sized fragment of 593 bp and of an abnormal
692 bp fragment in MF cells (lane 2), while only the normal-sized fragment is present in CF cells (lane 1). (b) Scheme of the
minigene constructs used for the analysis of the c.14646 + 2563C >T mutation. RYR1 intronic regions containing sequence of
the pseudo-exon, with (gray) or without (white) the mutation, were inserted into a pCIneo vector between exons -1 and +1.
An RT-PCR amplification using a forward primer in exon -1 and a reverse primer in exon +1 (arrows) was performed on
HEK 293 cells transfected with each minigene construct. Size analysis of the amplified fragments showed the presence of a
unique fragment of 620 bp in HEK293 cells transfected with the C construct (lane 1), corresponding to the normal splicing,
and of two fragments of 620 and 719 bp in HEK293 cells transfected with M construct (lane 2), corresponding to the inclusion
of the pseudo-exon. The identity of these fragments was confirmed by sequencing. CF, control fetal; MF, mutant fetal; RT-
PCR, reverse transcriptase–polymerase chain reaction.
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itself was sufficient to induce the insertion of a 99 bp se-
quence and that the mutation was of incomplete penetrance,
at least in HEK293 cells.
Exon-skipping strategy for removal of the 101bis
pseudo-exon
We have previously shown that the insertion of the 99 bp
pseudo-exon in RyR1 mRNA considerably lowered the
amount of the RyR1 protein in skeletal muscles (ind II:3)
without affecting the total amount of RyR1 transcripts
(Monnier et al., 2008). In the present study, we tested
whether a removal of the pseudo-exon by exon skipping
would restore the normal transcript expression, increase the
RyR1 protein expression and restore Ca2 + releases. We
designed seven 2¢O-methyl AONs (A to G; Table 1) with a
phosphorothioate backbone. The ability of these AONs to
force the skipping of the pseudo-exon was evaluated by
transfection of MF cells with each AON followed by their
differentiation into myotubes. Total RNA was extracted
from transfected myotubes and RT-PCR was performed on
RyR1 mRNA to amplify the region including exons 101 and
102 (Fig. 3a). The efficiency of each AON, evaluated by
quantification of the relative amount of abnormal splicing
compared with the total amount of PCR products (normal
transcript plus abnormal transcript), is presented on Figure
3b. Results showed that AON-D and AON-E, targeting
putative ESE of pseudo-exon 101bis, were the most efficient
in reducing the relative amount of abnormal splicing (re-
spectively, 37% and 70% of aberrant transcript reduction)
(Fig. 3b). These AONs were tested pair-wised by simulta-
neous transfection, and the D +E pair induced the most
effective exon skipping (Fig. 3b, 82% reduction of aberrant
transcript).
Lentiviral-induced skipping of pseudo-exon 101bis
Cell transfection with the different AONs allowed us to
select the most efficient ones. However, transfection induced
a large mortality of the cells incompatible with their subse-
quent characterization by calcium imaging. We therefore
decided to use lentiviral vectors to insert the AONs into the
cells. Recent advances have been made in antisense ap-
proaches using small nuclear RNAs (snRNAs) and U7
snRNP has been used for splicing modulation as it offers
many advantages: stability of the antisense sequence, specific
subcellular co-localization with target pre-mRNAs, and the
possibility of a long-term correction when introduced with
viral vectors (for review, cf. Benchaouir and Goyenvalle,
2012). U7-snRNAs with antisense sequences corresponding
to AONs D+E (called U7-D+E), and with a fluorescein-
isothiocyanate-labeled scramble AON (U7-Ctrl; Table 1) were
developed and inserted in lentiviral vectors. MF cells were
transduced with these vectors, differentiated, and analyzed for
RyR1 transcripts as previously described. As expected, RT-
PCR analysis showed that U7-D+E was very efficient in
skipping the 101bis pseudo-exon at the mRNA level (reduc-
tion of 80% of the relative amount of aberrant transcript),
while the U7-Ctrl had no effect (Fig. 3c and d). To assess that
no modification in the total amount of RyR1 transcripts was
observed between the three conditions (MF, MF+U7-CTRL,
and MF+U7-D+E), a PCR amplification of exons 103–105 of
RyR1 mRNA was performed and normalized to the reference
gene human acidic phosphoprotein—PO (data not shown).
FIG. 3. Test of AONs and lentiviral vectors to skip the 101bis pseudo-exon. (a) Seven AONs (A to G) were tested on MF
cells for their capacity to skip the pseudo-exon. MF cells were either not transfected (lane MF) or transfected with each of
the AONs (A to G) or with pairs of AONs (D +E or E +G). Cells were then induced to differentiate for 4 days and RT-PCR
was performed using same primers as in Fig. 2a. (b) Ratios of the amount of pseudo-exon-containing fragment versus the
total amount of amplified fragments (normal +pseudo-exon containing fragments) were calculated for each condition and
normalized to 1 for nontransfected MF cells. Results are given as mean – SEM of three experiments. (c) Lentiviral U7-
snRNA vectors containing antisense sequences corresponding to a nonrelevant control AON (U7-Ctrl) or to AONs D + E
(U7-D + E) were tested for their efficacy to skip the pseudo-exon. MF cells were either not transduced (lane MF), or
transduced with U7-Ctrl or U7-D + E vectors. Cells were then induced to differentiate for 4 days and RT-PCR was
performed as in (a). (d) Quantifications were performed as in (b), and the mean – SEM of four experiments is plotted.
***p < 0.001, Student’s t-test comparison of MF and MF U7-D +E cells. AONs, antisense oligonucleotides; snRNA, small
nuclear RNA.
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Skipping of the 101bis pseudo-exon in MF myotubes
increases amount of the RyR1 protein
and has a trophic effect
Quantification of the RyR1 protein in differentiated myo-
tubes could not be assessed using Western blot because RyR1
levels in whole cell homogenates were below the detection
limits of the technique. Therefore, we used image analysis
after immunofluorescent staining of the myotubes to evalu-
ate the relative amount of RyR1 compared with MyHC. Si-
milar image analysis methods have been used to quantify
dystrophin in dystrophinopathy muscle specimens (Taylor
et al., 2012). MyHC is a marker of differentiation whose ex-
pression increases during differentiation as observed for
RyR1. Hence, the quantification of RyR1 compared with
MyHC allowed to get rid of a possible altered differentiation
related to RyR1 reduction (Porter et al., 2002). The relative
amounts of RyR1 were evaluated in differentiated control
(CF) or mutant (MF) cells with or without transduction with
U7-Ctrl or with U7-D +E (Fig. 4a and c). RyR1 presented the
typical dotted pattern found in immunfluorescent staining of
muscle cells (Fig 4a insets). The relative amounts of RyR1 in
MF myotubes were about twofold lower than those in con-
trol CF myotubes (Fig. 4c), in good correlation with the re-
sults obtained in Western blot on muscle biopsy from ind
III:1 (Fig 1b). Treatment of MF cells with U7-Ctrl did not
change the level of RyR1 in myotubes. In contrast, treatment
of MF cells with U7-D +E raised the relative amounts of
RyR1 by approximately 1.5-fold (Fig. 4c).
In addition, an effect on the morphology of myotubes
concomitant to the increase in the relative amount of RyR1
was observed (Fig. 4a, b, and d). CF myotubes were signif-
icantly larger than MF myotubes (mean width 11– 0.4 lm
for CF myotubes and 4– 0.3 lm for MF myotubes, p < 0.001;
Fig.4d). Treatment of MF cells with U7-D +E induced a
significant increase in the width of myotubes compared
with untreated MF myotubes (mean width after treatment
7.8 – 0.3 lm, p< 0.001; Fig. 4d), with a redistribution of
widths toward those of normal CF myotubes (Fig. 4b).
Treatment of MF cells with U7-Ctrl had no effect on myo-
tubes’ width. Altogether, the lentiviral vector U7-D +E in-
creased RyR1 protein levels in MF cells, and favored a
restoration of the myotubes’ width.
Skipping of the 101bis pseudo-exon restores calcium
release capacities in affected cells
Functionality of the RyR1 protein was further tested by
calcium imaging. RyR1 is specifically expressed in differen-
tiated muscle cells, where it is the main intracellular calcium
channel involved in excitation–contraction coupling (Bril-
lantes et al., 1994; Kyselovic et al., 1994; Tarroni et al., 1997).
Depolarization of the muscle plasma membrane activates the
DHPR, which induces the opening of RyR1 and the release of
calcium from the sarcoplasmic reticulum. Therefore, activity
of RyR1 calcium channel was tested using calcium imaging
on cultured myotubes, by direct RyR1 stimulation using its
agonist CmC to assay the channel function of the restored
protein, and by plasma membrane depolarization to assay its
functional coupling to DHPR.
Calcium imaging experiments were performed on myo-
tubes produced from control CF cells, untreated MF cells, or
MF cells transduced with U7-Ctrl or U7-D +E (Fig. 5). Direct
RyR1 stimulation was first assayed by 4-Chloro-m-Cresol
(Fig. 5a), at a concentration resulting in maximal calcium
release (EC50& 100lM; Hermann-Frank et al., 1996). Addi-
tion of 500lM CmC to MF myotubes induced a calcium
release of reduced amplitude compared with CF myotubes
(DF/F0 = 0.24 – 0.06, n = 65 and DF/F0 = 1.21 – 0.11, n = 90, for
MF and CF myotubes, respectively, p< 0.0001), the peak
amplitude in MF myotubes being 20% of control CF myo-
tubes (Fig. 5a). This reduced calcium release was not signif-
icantly modified by transduction by U7-Ctrl, and fully
restored by transduction with U7-D +E ( p< 0.0001). Function
of the whole calcium release complex, and functional cou-
pling between DHPR and RyR1 were further tested by
membrane depolarization. Addition of 140mM KCl in the
presence of extracellular calcium induces a membrane de-
polarization close to 0mV, and leads to an almost maximal
stimulation of DHPR (Rezgui et al., 2005). It resulted in a
calcium release of much lower amplitude in MF cells (DF/
F0 = 0.77 – 0.03, n = 232) than in control CF cells (DF/
F0 = 2.18 – 0.18, n = 85, p< 0.0001), the amplitude of the peak
in MF myotubes corresponding to 35% of the amplitude
observed in CF myotubes (Fig. 5b). Transduction of MF cells
with U7-Ctrl had no effect, the amplitude of depolarization-
induced calcium release being identical to MF cells. On the
opposite, transduction with U7-D +E almost fully restored
normal depolarization, the amplitude of the calcium release
being not statistically different from control cells (DF/
F0 = 2.08 – 0.08, n = 252 for MF cells transduced with U7-D +E,
p = 0.64 between CF and MF U7-D +E, and p < 0.0001 be-
tween MF and MF U7-D +E). Using both stimulations (CmC
and KCl) the levels of calcium release in MF myotubes
treated with U7-D +E were therefore comparable to those in
control CF myotubes. These results demonstrated that the
RyR1 calcium channel restored by exon skipping using the
lentiviral vector U7-D +E was fully functional, correctly
coupled to DHPR, and able to sustain calcium release from
the sarcoplasmic reticulum to the cytoplasm.
Discussion
This study is the first example of an exon-skipping strat-
egy applied to a congenital core myopathy—in this case, a
severe form of CCD. The disease was caused by compound
heterozygous mutations on the RYR1 gene, inducing an
important drop in the amount of the RyR1 protein. The in-
tronic paternal mutation resulted in a reduction in the
amount of protein to 57% of a control muscle, the affected
heterozygous individuals being pauci symptomatic (Mon-
nier et al., 2008). In the severely affected child, the maternal
mutation induced a further reduction in RyR1 to 35% of the
amount observed in a control. We applied an exon-skipping
strategy to skip the paternal pseudo-exon in order to restore
an asymptomatic phenotype as observed for the mother. The
goal of this study was thus to increase the amount of the
RyR1 protein in affected muscle cells, and to test the func-
tionality of the restored protein.
Exon skipping was performed on fetal muscle MF cells
with the two mutations, using U7-AON vectorized in lenti-
viral vectors. The efficiency of exon skipping, shown by RT-
PCR at the mRNA level, was further evaluated at the protein
level by immunofluorescent staining and image analysis. The
relative amount of the RyR1 protein in MF myotubes was
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reduced compared with CF myotubes, and significantly re-
stored after treatment of MF cells by U7-D +E lentiviral
vector. The precise evaluation of the amount of RyR1 in
treated MF cells was not possible, but theoretically could not
reach the amount in control cells because of the conjugated
effect of the uncorrected maternal mutation and the incom-
plete skipping of pseudo-exon 101bis. Nevertheless, we
showed that the abnormal RyR1 transcript was reduced five
times by exon skipping, which suggested that the amount of
the RyR1 protein in corrected cells was probably almost
similar to the amount in the asymptomatic mother.
Functional studies using calcium imaging on MF myo-
tubes allowed us to evaluate whether the RyR1 protein re-
covered by exon skipping was functional. Amplitude of
FIG. 4. Lentiviral vector treatments restore amounts of the RyR1 protein and affect the size of differentiated MF cells. (a)
Control CF cells, untreated MF cells, or MF cells treated with U7-Ctrl vector or with U7-D +E vector were induced to
differentiate for 8 days, and immunolabeled with antibodies against RyR1 and myosin heavy chain (MyHC). A magnification
of RyR1 labeling is presented in the insets. Scale bars = 20lm. (b) Width distribution of myotubes. Each myotube was
classified in one of the four categories according to its largest measured width ( < 2lm, 2–5 lm, 5–8 lm, and > 8 lm). The
distribution of the myotube population in the four categories is represented for each condition (number of myotubes
indicated in (d). (c) Quantification by image analysis of the mean fluorescence intensity of RyR1 staining in myotubes relative
to the mean fluorescence intensity of MyHC staining, presented as mean – SEM. The mean fluorescence intensity of MyHC
staining is not statistically different between the different conditions. The number of myotubes used for quantification is
indicated in each bar of the plot. (d) Mean width of myotubes was calculated and results given in lm as mean– SEM of the
number of myotubes indicated in each bar. ***p < 0.001, ANOVA analysis followed by Bonferroni multiple comparison test.
ANOVA, analysis of variance.
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calcium releases in untreated MF cells was about 20–35% of
that in control cells, in good correlation with the massive
reduction in the RyR1 amount observed in the proband III.1
(remaining RyR1 quantity evaluated to 35%). Treatment of
MF myotubes with the U7-D +E vector resulted in calcium
releases of amplitude equivalent to that observed in control
myotubes. This increase in calcium releases of amplitude
showed that restored RyR1 was functional. Moreover, it
suggested that the restored level of RyR was sufficient to
trigger calcium release of normal amplitude, raising the
question of the quantity of RyR1 necessary for a correct
muscle function. Interestingly, individual II-3, with an RyR1
amount of 57% of a control, showed only mild signs of
muscle weakness. Patients with null mutations, that is, re-
sulting in the absence of expression of one allele of RYR1 and
leading to a 50% reduction in the amount of RyR1 at a
protein level, have been shown to be asymptomatic or to
present with mild phenotype (Zhou et al., 2007; Monnier
et al., 2008). In the same way, and although no muscle biopsy
was available to precisely quantify RyR1, the presence of a
heterozygous splice mutation in the asymptomatic mother
(ind II-1) was likely to result in a reduced expression of
RyR1. On the basis of this observation, it can thus be hy-
pothesized that reaching an RyR1 expression of 100% is not
necessary to sustain a normal muscle function. Such an ob-
servation has already been done when exon-skipping strat-
egy was applied to the chloride channel in myotonic
dystrophy (Wheeler et al., 2007).
Our data demonstrate that exon skipping could be a rel-
evant therapeutic strategy for an RYR1 splicing mutation
resulting in the inclusion of a pseudo-exon and involved in
CCD, because (i) the restored protein is a completely normal
one, in contrast with the truncated dystrophin or the mini-
dysferlin re-expressed after exon skipping in Duchenne
muscular dystrophy (DMD) or dysferlinopathy (Goyenvalle
et al., 2004; Wein et al., 2010), and (ii) it is not necessary to
reach a full correction of the abnormal transcript and to re-
store 100% of the normal protein to reach normal levels of
calcium release. Splice mutations account for 10–15% of
RYR1mutations involved in CCD, and pseudo-exon creating
mutations constitute about 1–2% of RyR1 mutations identi-
fied up to now. This proportion is probably underestimated
because these mutations are difficult to identify and need the
analysis of RyR1 mRNA from a muscle biopsy. Exon-skipping
strategy could most probably not be applied to any RYR1
mutation, and it would not be possible to suppress a whole
FIG. 5. Lentiviral vector treatments restore the RyR1 calcium release activity in differentiated MF cells. Calcium imaging
performed on control CF cells (empty square), untreated MF cells (black square), and MF cells treated with U7-Crtl vector
(black triangle) or with U7-D +E vector (gray square), and differentiated for 8–10 days before calcium imaging. (a) Fluor-
escence variation curves induced by application during 50 sec (black bar) of CmC (500 lM) in the presence of 2mM external
calcium, presented as mean (symbols) – SEM (dotted lines). The maximal amplitude of the peak for each curve is presented in
the bar plots on the right, with the number of myotubes analyzed in each bar. (b) Fluorescence variation curves induced by
membrane depolarization (KCl 140mM) applied during 50 sec (black bar) in the presence of 2mM external calcium, pre-
sented as mean (symbols) – SEM (dotted lines). ****p < 0.0001, ANOVA analysis followed by Bonferroni multiple comparison
test. CmC, 4-Chloro-m-Cresol.
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exon affected by a point mutation, as it has been done for
dystrophin or dysferlin. Indeed, a number of the central ex-
ons of dystrophin have been shown to be skippable, with no
or only mild effect. This is not the case for RyR1, in which no
exon has been identified as needless up to now.
An unexpected observation was the effect of exon skip-
ping on myotube morphology: MF myotubes were very thin
compared with control myotubes, and this morphologic
feature was reversed by transduction with U7-D +E lentivi-
rus. This effect on myotube morphology was specific of the
vector inducing a skipping of the aberrant RyR1 pseudo-
exon. An effect of the aberrant transcript per se cannot be
ruled out (either a toxic effect on myotube differentiation or
an induction of a degradation pathway), but it was most
probably the increase in the normal RyR1 transcript/protein
that was the cause of this trophic effect. The molecular
mechanisms underlying the link between restoration of the
RyR1 normal mRNA/protein and the trophic effect on
myotubes are not yet understood. They could be related to
an altered differentiation in the absence of RyR1. Even if
expressed mainly in differentiated muscle cells with a major
function in the calcium releases for contraction, other func-
tions could be associated to this calcium channel in early
maturation steps. The RyR1 protein has already been de-
scribed as important for normal myofiber morphogenesis
and muscle development in vivo. Indeed, the RyR1-null mice
exhibited muscular degeneration associated with excitation–
contraction uncoupling (Takeshima et al., 1994; Barone et al.,
1998). Similar muscle degeneration was observed in the mdg
mouse line, devoid of the alpha-1 subunit of DHPR (Banker,
1977; Chaudhari, 1992). Therefore, deletion of RyR1 or alpha-
1 could alter the first steps of muscle formation. We have also
recently observed that in vivo downregulation of the alpha-1
subunit of skeletal muscle DHPR induced massive muscle
atrophy (Pietri-Rouxel et al., 2010). The situation is less clear
for in vitro studies using cultured cells. Primary cultures
produced from atrophic RyR1-null muscles or alpha-1-null
muscles are, nevertheless, still able to form myotubes in vitro.
In contrast, perturbation of intracellular calcium levels by
several drugs targeting either RyR1 or its partner the DHPR
inhibits myoblast differentiation (Seigneurin-Venin et al.,
1996; Porter et al., 2002). Therefore, it is tempting to speculate
that the presence of RyR1 and DHPR, or the precise control
of intracellular calcium level, is important not only for
muscle contraction during the excitation–contraction cou-
pling, but also for myotube formation and/or for mainte-
nance of muscle mass. In this case, the trophic effect of U7
exon-skipping vectors on MF cells reflects the restoration of a
functional RyR1 protein in an indirect manner.
Overall, the present study describes a successful exon-
skipping strategy for the correction of the genetic cause of a
core myopathy in affected human cells. In the case studied
here, the severe form of CCD was caused by a massive drop
of RyR1 calcium channel expression, and the exon-skipping
strategy was efficient both to increase the amount and to
restore the activity of RyR1. This is the first time that such an
efficient functional restoration is observed after exon skip-
ping. In DMD, the ongoing clinical trials demonstrate an
increase in dystrophin expression up to 18% of normal level
after exon skipping, but this level seems too low to restore a
correct muscle function. It has been shown very recently that
molecules able to block RyR1 (dantrolene, ryanodine, S107)
improve the efficiency of exon skipping in DMD patients
cells (Kendall et al., 2012). The underlying mechanisms are
still unknown, but it can be hypothesized that the improved
exon-skipping efficiency in presence of these chemicals is
related to their ability to reduce the amount of calcium re-
leased in the cytoplasm, which could affect the splicing
through the calcium regulation of spliceosomal components
(Krebs, 2009). In the case presented here, the cytosolic cal-
cium reduction is a direct consequence of the mutation, and
therefore could also be responsible for the high efficiency of
the exon skipping. Therefore, this model study paves the
way for therapies for core myopathies, even beyond similar
RYR1 splicing alterations. Indeed, other therapies targeting
mRNA such as trans-splicing or exon exchange are extremely
promising, but as they have a much lower efficiency (Lorain
et al., 2010) their use in future therapies is related to im-
provement of splicing. If improved splicing in skeletal
muscle is correlated to reduced function of RyR1, then
therapies based on exon exchange could be assayed for pa-
tients with any RYR1 mutation leading to a reduced RyR1
function, for whom it would be possible to successfully ex-
change the mutant exon(s) for normal one(s). All the tools
developed in this work (calcium imaging, myotube mor-
phology, etc.) will help for evaluation of any gene therapy
aimed at the restoration of functional RyR1.
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